Celerion joins capability cluster to boost patient access

- Last updated on GMT

Celerion has improved access to patients with respiratory diseases by joining a UK capability cluster.

Joining the UK respiratory therapeutic capability cluster gives Celerion’s Northern Ireland site access to patients for Phase I trials.

We have seen an increasing demand for conducting Phase I studies in patients with access to more specialised techniques. This collaboration allows Celerion to address this need and assist clients to gain insight to data earlier​”, said Phil Bach, VP of clinical research at Celerion.

Related topics: Clinical Development

Related news